AI-based cfDNA fragmentome liquid biopsy can detect early liver fibrosis, cirrhosis, and indicate broader chronic disease signals.
Key Details
- 1Johns Hopkins team applied AI and genome-wide cfDNA fragmentation analysis to diagnose early liver fibrosis and cirrhosis.
- 2Study analyzed samples from 1,576 people with liver disease and comorbidities using whole-genome sequencing.
- 3AI algorithms identified disease-specific fragmentation patterns, enabling high sensitivity detection of early liver disease.
- 4Current clinical tests often miss early fibrosis and only detect cirrhosis around 50% of the time.
- 5Prototype assay also signaled risk for other chronic diseases, such as cardiovascular and inflammatory conditions.
- 6Technology builds upon earlier cancer fragmentome studies, focusing now on non-cancer chronic conditions.
Why It Matters
Early detection of liver fibrosis is critical because it is reversible at early stages, potentially preventing progression to cirrhosis and cancer. This AI-enabled cfDNA approach could expand the role of noninvasive liquid biopsy in radiological diagnostics and broader chronic disease management.
Source
EurekAlert
Related News
•EurekAlert
NIH Invests Additional $12.6M in USC-Led Imaging AI for Alzheimer's
NIH has renewed and expanded its support for a USC-led consortium developing AI to decode and treat Alzheimer's using imaging and genomic data.
•EurekAlert
USC Unveils Joint Biomedical Engineering Department Bridging Medicine, Engineering, and Imaging
USC's medical and engineering schools launch a joint biomedical engineering department to accelerate interdisciplinary research and innovation, including imaging and AI.
•EurekAlert
AI Predicts Risks for Outpatient Stem Cell Therapy in Myeloma
Researchers use machine learning to predict adverse events during stem cell therapy for multiple myeloma, improving outpatient safety.